Announcements Trials
Browse Landscape

Phase

Phase NA 15Phase 1 7Phase 2 5Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 8Active not recruiting 7Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Recurrence 1Pancreatic Intraductal Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × X-Rays × Clear all
NCT01013649 2026-02-23

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
546 enrolled 29 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms

NCT02636634 2016-04-11

CV-METANEC

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
90 enrolled
CNS

Brain Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡